HC Wainwright Forecasts argenex's Q4 Earnings (NASDAQ:ARGX)

Key Points

• HC Wainwright raised its Q4 2026 EPS estimate for argenx to $7.00 from $6.47 and kept a Buy rating with a $940 price target.
• argenx recently reported Q1 2026 EPS of $5.52, missing the $5.74 consensus, while revenue of $1.31 billion also came in below expectations.
• Despite the earnings miss, other analysts remain constructive, with multiple firms raising price targets and the stock still carrying an average Moderate Buy rating and roughly $1,017.78 average target price.

argenex SE (NASDAQ:ARGX - Free Report) - Stock analysts at HC Wainwright increased their Q4 2026 earnings per share estimates for shares of argenex in a research note issued on Friday, May 8th. HC Wainwright analyst D. Tsao now forecasts that the company will earn $7.00 per share for the quarter, up from their previous estimate of $6.47. HC Wainwright has a "Buy" rating and a $940.00 price target on the stock. The consensus estimate for argenex's current full-year earnings is $23.96 per share.

argenex (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported $5.52 earnings per share for the quarter, missing the consensus estimate of $5.74 by ($0.22). The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.44 billion. argenex had a net margin of 31.31% and a return on equity of 33.28%.

ARGX has been the subject of a number of other reports. Deutsche Bank Aktiengesellschaft upgraded argenex from a "hold" rating to a "buy" rating in a research note on Tuesday, March 10th. Oppenheimer cut their price objective on argenex from $1,060.00 to $1,014.00 and set an "outperform" rating for the company in a research note on Thursday, April 2nd. Wells Fargo & Company boosted their price objective on argenex from $1,247.00 to $1,260.00 and gave the company an "overweight" rating in a research note on Friday. Zacks Research raised argenex from a "strong sell" rating to a "hold" rating in a report on Friday, February 20th. Finally, Wall Street Zen cut argenex from a "buy" rating to a "hold" rating in a report on Sunday, March 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $1,017.78.

argenex Stock Performance

Shares of argenex stock opened at $782.17 on Monday. The stock's fifty day moving average is $755.88 and its 200 day moving average is $817.54. The stock has a market cap of $48.64 billion, a P/E ratio of 34.83, a P/E/G ratio of 1.31 and a beta of 0.46. argenex has a one year low of $510.05 and a one year high of $934.62.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARGX. M&T Bank Corp grew its position in argenex by 20,977.7% in the fourth quarter. M&T Bank Corp now owns 778,610 shares of the company's stock worth $654,772,000 after acquiring an additional 774,916 shares in the last quarter. Sands Capital Management LLC grew its position in argenex by 2,046.6% in the fourth quarter. Sands Capital Management LLC now owns 356,870 shares of the company's stock worth $300,110,000 after acquiring an additional 340,245 shares in the last quarter. Invesco Ltd. grew its position in argenex by 390.4% in the fourth quarter. Invesco Ltd. now owns 416,408 shares of the company's stock worth $350,178,000 after acquiring an additional 331,489 shares in the last quarter. Wellington Management Group LLP grew its position in argenex by 80.1% in the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company's stock worth $538,408,000 after acquiring an additional 324,653 shares in the last quarter. Finally, Two Sigma Investments LP grew its position in argenex by 570.3% in the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company's stock worth $216,961,000 after acquiring an additional 250,278 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company's stock.

Key argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Guggenheim raised its price target on argenx to $1,135 and kept a buy rating, implying substantial upside from current levels. Guggenheim Raises ARGX Price Target
• Positive Sentiment: Wells Fargo also increased its price target to $1,260 and reiterated an overweight rating, signaling continued confidence in argenx’s long-term growth prospects. Wells Fargo Raises ARGX Price Target
• Neutral Sentiment: argenx reported Q1 2026 results and a business update, with investors parsing the details of the quarter and management’s outlook. argenx Q1 2026 Financial Results and Business Update
• Negative Sentiment: The company posted earnings of $5.52 per share, below the $5.79 consensus estimate, and revenue of $1.31 billion also missed expectations, which is likely weighing on the stock. Argenx Tops Earnings Expectations Despite Slight Revenue Shortfall

argenex Company Profile

argenx NASDAQ: ARGX is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx's research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company's lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.